Phase-II Clinical Trial. A multi-center, randomized, double blind, placebo and active-controlled study with exploratory dose ranging, to investigate the efficacy and safety of 16 weeks treatment with subcutaneous QGE031 in asthma patients not adequately controlled with high-dose inhaled corticosteroid plus long-acting β-2agonists,